In vitro activity of fleroxacin and 14 other antimicrobials against slime- and non-slime-producing Staphylococcus epidermidis.
The in vitro activity of the 4-quinolone compound fleroxacin (Ro-23-6240) was compared with that of 14 other antimicrobials against a total of 50 recent clinical isolates of 25 slime- and 25 non-slime-producing coagulase-negative staphylococci. Susceptibility testing (MIC/MBC) was performed by a microtiter broth dilution technique and the combination effect of fleroxacin plus rifampin was studied by checkerboard titration in microtiter trays. Fleroxacin inhibited the most slime- and non-slime producing coagulase-negative staphylococci at MIC90 0.25 and I micrograms/ml, respectively. Overall fleroxacin was as active or even better as ofloxacin, cefotiam, cefazolin, cefamandole, clindamycin or vancomycin but 2- to 8-fold less active than rifampin. The fleroxacin-rifampin combination was indifferent in 17%, additive in 78.7% and synergistic in 4.3%.
Kropec
A
A
Department of Hospital Epidemiology, University Hospital, Freiburg, FRG.
Daschner
F
F
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D003030:Coagulase; D004352:Drug Resistance, Microbial; D016576:Fleroxacin; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity
D000900:Anti-Bacterial Agents; D003030:Coagulase; D002939:Ciprofloxacin; D016576:Fleroxacin